Recombinant Therapeutic Proteins: Delivering a $53 Billion Mature Market by 2010

Introduction

The discovery and development of recombinant DNA technology formed the cornerstone of the modern medical biotechnology industry. With a market valued at almost $32 billion in 2003, the changing dynamics of the recombinant therapeutic proteins market will have a significant impact on numerous companies and therapy areas. This analysis seeks to identify and evaluate the key market dynamics to 2010. 

Scope

> Reviews the industry’s current R&D pipeline and recent business model evolution, and deal activity of leading biotech and pharmaceutical companies

> Phase-to-phase analysis calculates the return of the sector’s current pipeline of 104 recombinant products to 2010

> Market segmentation and forecasting by leading players, key protein classes, top-selling brands and therapeutic foci reveal key revenue trends to 2010 

Report Highlights

> Despite an increasing interest in protein inhibitors, fusion proteins and tissue growth factors, innovation-driven income will not be sufficient to drive market growth, as the sector’s drug pipeline, with 28 new approvals in the next six years, will account for just 9% of the market in 2010.

> The recombinant protein market will continue to rely on blockbuster revenue derived from 16 brands. Between 2001 and 2003 blockbuster market share increased from 51.8% to 64.3% and is forecast to remain above 58% to 2010. Successful lifecycle management of these 16 core brands will be critical to continued market development.

> Hematology, diabetes and endocrinology and oncology will be the most valuable therapy areas for recombinant proteins over the forecast period. However; while the latter two therapy areas reflect strong opportunities for future investment, generating 44% of all pipeline products, novel products in hematology are few and far between. 

Reasons to Purchase

> Examine the portfolios of 112 companies by probing Datamonitor’s interactive recombinant therapeutic proteins analysis and forecasting tool

> Identify therapy area and class-based market opportunities and target product development and lifecycle management strategies accordingly

> Assess current corporate strategies and evaluate partnering opportunities for new product development, reformulation or market expansion  

Pages: 334 Format: PDF Publication: May 2004 

Publisher: Datamonitor Drug Discovery Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Drug_Discovery.html#a123